Hawaii SB967 mandates insurance coverage for intravenous ketamine therapy to treat depression.

Hawaii SB967 requires both Medicaid and private insurance to cover intravenous ketamine therapy for depression in qualifying patients. The bill also appropriates state funds to the Medicaid program to facilitate this coverage. The changes will take effect on July 1, 2025, with Medicaid coverage contingent on approval of the Hawaii Medicaid state plan by the Centers for Medicare and Medicaid Services.

Hawaii SB967 mandates insurance coverage for intravenous ketamine therapy to treat depression.

Hawaii SB967 requires both Medicaid and private insurance to cover intravenous ketamine therapy for depression in qualifying patients. The bill also appropriates state funds to the Medicaid program to facilitate this coverage. The changes will take effect on July 1, 2025, with Medicaid coverage contingent on approval of the Hawaii Medicaid state plan by the Centers for Medicare and Medicaid Services.